Hematopoietic cancer and angiogenesis.
The growth of solid tumors is certainly angiogenesis dependent. However, the role of angiogenesis in the growth and survival of leukemias and other hematological malignancies has only been rendered evident since 1994 in a series of demonstrations showing that the progression of several forms is clearly related to their degree of angiogenesis. Here, we present an overview of the literature concerning the relationship between angiogenesis and disease progression in several hematological malignancies and the recent advances in antiangiogenesis in these diseases and we describe the most important active substances, preclinical and clinical data, and future perspectives.
Ribatti
Domenico
D
Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy. ribatti@anatomia.uniba.it
Scavelli
Claudio
C
Roccaro
Aldo M
AM
Crivellato
Enrico
E
Nico
Beatrice
B
Vacca
Angelo
A
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D049109:Cell Proliferation; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000166:cytology; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology; D008223:Lymphoma / Q000473:pathology; D020782:Matrix Metalloproteinases / Q000378:metabolism; D008954:Models, Biological; D009101:Multiple Myeloma / Q000473:pathology; D009389:Neovascularization, Pathologic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology; D017154:Stromal Cells / Q000166:cytology; D013792:Thalidomide / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D020782:Matrix Metalloproteinases